Previous studies of methylphenidate in epilepsy patients have suffered from small numbers and methodological issues, such as lack of blinding.
© lassede signen/Shutterstock.com
Interesting Neuro: Tumor Tx and Stroke Recovery
March news includes possible brain tumor therapies, a study exploring mechanisms underlying demyelination-induced seizures, and VNS post stroke.
Epilepsy, Syncope, or Both?
Common presentations between epilepsy and syncope complicate the differential diagnosis, making syncope the most frequent misdiagnosis in epilepsy.
Epilepsy Risk with Depression
Researchers evaluated several databases to determine whether or not depression has a causative role on epilepsy, or vice versa.
Top 10 Neurology Apps
Ten general and disease-specific apps for neurologists include assessment scales, anatomical diagrams, and interactive clinical decision support.
Interesting Neuro: Stroke Risks & Treatment
February news includes stroke risk with Alzheimer disease & migraine, neonatal hemorrhagic stroke, and head trauma in sports.
Incident Epilepsy Risk among the Elderly
Stroke is the most common cause of epilepsy in older adults, but there is limited information about rates and risk factors in this population.
Methylphenidate: Effect on Cognition in Epilepsy
Pregnancy Outcomes with Pregabalin Use
In this Medical News Minute, Dr. Bobby Lazzara highlights possible birth defects resulting from women taking pregabalin during pregnancy.
Modeling Simulations to Predict AED Efficacy
Researchers used simulations to predict the outcomes of epilepsy patients with partial-onset seizures converting to Aptiom monotherapy (800 mg QD).
Potential Treatment for SRSE
Research leading up to the ongoing phase 3 trial of SAGE-547, a potential drug for super-refractory status epilepticus, was presented at AAN 2016.
Antiepileptic Drug Choice: Patient vs Neurologist
Do you and your patients with epilepsy agree on treatment decisions? A national survey compares AED attribute preferences of patients and neurologists.
Interesting Neuro: Epilepsy Outcomes & Vitamin D
January news includes the first FDA-approved drug for spinal muscular atrophy, various epilepsy treatments & vitamin D’s impact on Alzheimer & headache.
By clicking Accept, you agree to become a member of the UBM Medica Community.